Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion evidence source_evidence_literature NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion SIO_000772 14604974 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion wasDerivedFrom befree-20140225 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion wasGeneratedBy ECO_0000203 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- befree-20140225 importedOn "2014-02-25" NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.